Abstract :
Peripheral T-cell lymphomas (PTCL) are a heterogeneous group of relatively rare lymphoid malignancies. In Europe they account for approximately 15% of all lymphomas. Results of treatment of aggressive PTCL are poor and differ significantly from what has been achieved in recent years in the treatment of B-cell lymphomas. Currently, only patients with anaplastic large cell lymphoma ALK (+) have more than 50% chance of long-term survival. CHOP protocol should not be considered a standard of care, however, in the absence of alternatives it is used in clinical practice. Consolidation therapy with autologous haematopoietic stem cell transplantation (ASCT) improves response rate. This review summarizes treatment options for most common aggressive PTCL: anaplastic large cell lymphoma, angioimmunoblastic lymphoma, peripheral T-cell lymphoma NOS, NK/T-cell lymphoma, enteropathy associated lymphoma and hepatosplenic T-cell lymphoma.
